Lotem J, Berrebi A, Sachs L
Leuk Res. 1985;9(2):249-58. doi: 10.1016/0145-2126(85)90087-6.
Bone marrow cells from 9 patients with acute myeloid leukemia and 1 patient with a blast crisis of chronic myeloid leukemia were cultured to determine their ability to be induced to differentiate by different chemotherapeutic compounds. Five of these 10 patients showed differentiation to granulocytic and/or monocytic cells by culture with medium containing the myeloid cell differentiation-inducing protein MGI-2. Actinomycin D induced differentiation in cells from 2 of the patients who did not show differentiation with MGI-2 containing medium. In these 7 patients there was an increase in the ratio of differentiated myeloid cells to blasts. None of these 10 patients showed induction of differentiation by cytosine arabinoside, adriamycin, or daunomycin, but treatment with these compounds showed in some patients an increase in the ratio of differentiated myeloid cells to blasts. The results indicate that this ratio can be increased by differentiation and also in some patients by toxicity to blast cells. With dexamethasone or vinblastine there was no induction of differentiation and no increase in this ratio in any of the 10 patients tested. After in vivo chemotherapy with low dose cytosine arabinoside, cells from one patient showed a similar response in culture to actinomycin D as cells before chemotherapy, whereas in another patient the cells had acquired the ability to respond to actinomycin D. In contrast, after high-dose in vivo chemotherapy with cytosine arabinoside and daunomycin, cells from a third patient seemed to have lost the ability to differentiate in vitro by MGI-2 containing medium or actinomycin D. The results indicate that pre-screening for differentiation-inducing compounds and compounds that show toxicity to blast cells should be useful to select the appropriate compounds to be used for therapy, and that it is advisable to screen the cells both before and after initiation of therapy.
对9例急性髓系白血病患者和1例慢性髓系白血病急变期患者的骨髓细胞进行培养,以确定它们被不同化疗化合物诱导分化的能力。这10例患者中有5例在含有髓系细胞分化诱导蛋白MGI-2的培养基中培养后,分化为粒细胞和/或单核细胞。放线菌素D在未用含MGI-2培养基诱导分化的2例患者的细胞中诱导了分化。在这7例患者中,分化的髓系细胞与原始细胞的比例增加。这10例患者中无一例被阿糖胞苷、阿霉素或柔红霉素诱导分化,但这些化合物治疗在一些患者中显示分化的髓系细胞与原始细胞的比例增加。结果表明,该比例可通过分化增加,在一些患者中也可通过对原始细胞的毒性增加。在10例受试患者中,使用地塞米松或长春碱均未诱导分化,且该比例未增加。用低剂量阿糖胞苷进行体内化疗后,1例患者的细胞在培养中对放线菌素D的反应与化疗前相似,而另1例患者的细胞获得了对放线菌素D的反应能力。相反,在用阿糖胞苷和柔红霉素进行高剂量体内化疗后,第3例患者的细胞似乎失去了在含MGI-2培养基或放线菌素D中体外分化的能力。结果表明,对诱导分化化合物和对原始细胞有毒性的化合物进行预筛选,有助于选择合适的治疗化合物,并且在治疗开始前后对细胞进行筛选是可取的。